Information Provided By: 
Fly News Breaks for June 3, 2019
IOVA
Jun 3, 2019 | 07:34 EDT
Oppenheimer analyst Mark Breidenbach raised his price target for Iovance Biotherapeutics to $30 from $25 after the company presented updated results from its InnovaTIL-01 and -04 trials that were "clear highlights" of the ASCO meeting. The analyst believes the growing durability substantially improves the commercial profile of TIL therapy and based on the data, Breidenbach is increasing Probability of Success for both programs. He reiterates an Outperform rating on the shares.
News For IOVA From the Last 2 Days
There are no results for your query IOVA
